Phase I study of tumor Ag-loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer

References

• Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18: 767–811
   PubMed Web of Science ®Google Scholar
• Felzmann T, Gadner H, Holter W. Dendritic cells as adjuvants in antitumor immune therapy. Onkologie 2002; 25: 456–64
   Google Scholar
• Geiger JD, Hutchinson RJ, Hohenkirk LF, et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001; 61: 8513–9
   PubMed Web of Science ®Google Scholar
• Dagher R, Long LM, Read EJ, et al. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med Pediatr Oncol 2002; 38: 158–64
   PubMedGoogle Scholar
• Labeur MS, Roters B, Pers B, et al. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol 1999; 162: 168–75
   PubMed Web of Science ®Google Scholar
• Mazzaccaro RJ, Gedde M, Jensen ER, et al. Major histocompatibility class I presentation of soluble antigen facilitated by Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA 1996; 93: 11786–91
   Google Scholar
• Simmons CP, Mastroeni P, Fowler R, et al. MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants. J Immunol 1999; 163: 6502–10
   PubMed Web of Science ®Google Scholar
• Cho HJ, Takabayashi K, Cheng PM, et al. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nat Biotechnol 2000; 18: 509–14
   PubMed Web of Science ®Google Scholar
• Hamilton SE, Tvinnereim AR, Harty JT. Listeria monocytogenes infection overcomes the requirement for CD40 ligand in exogenous antigen presentation to CD8(+) T cells. J Immunol 2001; 167: 5603–9
   Google Scholar
• Sigal LJ, Crotty S, Andino R, Rock KL. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 1999; 398: 77–80
   PubMed Web of Science ®Google Scholar
• Mueller SN, Jones CM, Smith CM, et al. Rapid cytotoxic T lymphocyte activation occurs in the draining lymph nodes after cutaneous herpes simplex virus infection as a result of early antigen presentation and not the presence of virus. J Exp Med 2002; 195: 651–6
   PubMedGoogle Scholar
• Le Bon A, Etchart N, Rossmann C, et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 2003; 4: 1009–15
   PubMed Web of Science ®Google Scholar
• Ridge JP, Di-Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998; 393: 474–8
   PubMed Web of Science ®Google Scholar
• Bennett SR, Carbone FR, Karamalis F, et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998; 393: 478–80
   PubMed Web of Science ®Google Scholar
• Schoenberger SP, Toes RE, van-der-Voort EI, et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions. Nature 1998; 393: 480–3
   PubMed Web of Science ®Google Scholar
• Lefrancois L, Altman JD, Williams K, Olson S. Soluble antigen and CD40 triggering are sufficient to induce primary and memory cytotoxic T cells. J Immunol 2000; 164: 725–32
   Google Scholar
• Liu Y-J, Kanzler H, Soumelis V, Gilliet M. Dendritic cell lineage, plasticity and cross-regulation. Nat Immunol 2001; 2: 585–9
   PubMed Web of Science ®Google Scholar
• Kalinski P, Hilkens CM, Wierenga EA, Kapsenberg ML. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 1999; 20: 561–7
   PubMedGoogle Scholar
• Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3: 133–46
   PubMed Web of Science ®Google Scholar
• Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7: 145–73
   PubMed Web of Science ®Google Scholar
• Felzmann T, Huttner KG, Breuer SK, et al. Semi-mature IL-12 secreting dendritic cells present exogenous antigen to trigger cytolytic immune responses. Cancer Immunol Immunother 2005; 54: 769–80
   Google Scholar
• Hüttner KG, Breuer SK, Paul P, et al. Generation of potent anti-tumor immunity in mice by interleukin-12-secreting dendritic cells. Cancer Immunol Immunother 2005; 54: 67–77
   PubMedGoogle Scholar
• Langenkamp A, Messi M, Lanzavecchia A, Sallusto F. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol 2000; 1: 311–6
   PubMed Web of Science ®Google Scholar
• Kager L, Zoubek A, Potschger U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003; 21: 2011–8
   PubMed Web of Science ®Google Scholar
• Felzmann T, Witt V, Wimmer D, et al. Monocyte enrichment from leukapharesis products for the generation of DCs by plastic adherence, or by positive or negative selection. Cytotherapy 2003; 5: 391–8
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Steinman RM, Krasovsky J, et al. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001; 193: 233–8
   PubMed Web of Science ®Google Scholar
• Medzhitov R, Janeway CA, Jr. Decoding the patterns of self and nonself by the innate immune system. Science 2002; 296: 298–300
   PubMed Web of Science ®Google Scholar
• Kalinski P, Hilkens CM, Snijders A, et al. IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells. J Immunol 1997; 159: 28–35
   PubMed Web of Science ®Google Scholar
• Kalinski P, Schuitemaker JH, Hilkens CM, Kapsenberg ML. Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+ CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. J Immunol 1998; 161: 2804–9
   PubMed Web of Science ®Google Scholar
• Kaiser A, Bercovici N, Abastado JP, Nardin A. Naive CD8+ T cell recruitment and proliferation are dependent on stage of dendritic cell maturation. Eur J Immunol 2003; 33: 162–71
   PubMed Web of Science ®Google Scholar
• Camporeale A, Boni A, Iezzi G, et al. Critical impact of the kinetics of dendritic cell activation on the in vivo induction of tumor-specific T lymphocytes. Cancer Res 2003; 63: 3688–94
   PubMed Web of Science ®Google Scholar
• Rock KL, Gamble S, Rothstein L. Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science 1990; 249: 918–21
   PubMed Web of Science ®Google Scholar
• Bevan MJ. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med 1976; 143: 1283–8
   PubMed Web of Science ®Google Scholar
• Melief CJ. Mini-review: regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming?. Eur J Immunol 2003; 33: 2645–54
   PubMed Web of Science ®Google Scholar
• Eggert AA, Schreurs MW, Boerman OC, et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 1999; 59: 3340–5
   PubMed Web of Science ®Google Scholar
• Lappin MB, Weiss JM, Delattre V, et al. Analysis of mouse dendritic cell migration in vivo upon subcutaneous and intravenous injection. Immunology 1999; 98: 181–8
   PubMed Web of Science ®Google Scholar
• Serody JS, Collins EJ, Tisch RM, et al. T cell activity after dendritic cell vaccination is dependent on both the type of antigen and the mode of delivery. J Immunol 2000; 164: 4961–7
   PubMed Web of Science ®Google Scholar
• Fong L, Brockstedt D, Benike C, et al. Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 2001; 166: 4254–9
   PubMed Web of Science ®Google Scholar
• Lambert LA, Gibson GR, Maloney M, et al. Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity. Cancer Res 2001; 61: 641–6
   PubMed Web of Science ®Google Scholar
• Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2: 52–8
   PubMed Web of Science ®Google Scholar
• Chakraborty NG, Sporn JR, Tortora AF, et al. Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma. Cancer Immunol Immunother 1998; 47: 58–64
   PubMed Web of Science ®Google Scholar
• Brossart P, Wirths S, Stuhler G, et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000; 96: 3102–8
   PubMed Web of Science ®Google Scholar
• Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328–32
   PubMed Web of Science ®Google Scholar
• Thurner B, Haendle I, Roder C, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190: 1669–78
   PubMed Web of Science ®Google Scholar
• Morse MA, Coleman RE, Akabani G, et al. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 1999; 59: 56–8
   PubMed Web of Science ®Google Scholar
• Barratt-Boyes SM, Zimmer MI, Harshyne LA, et al. Maturation and trafficking of monocyte-derived dendritic cells in monkeys: implications for dendritic cell-based vaccines. J Immunol 2000; 164: 2487–95
   PubMed Web of Science ®Google Scholar
• Okada N, Tsujino M, Hagiwara Y, et al. Administration route-dependent vaccine efficiency of murine dendritic cells pulsed with antigens. Br J Cancer 2001; 84: 1564–70
   PubMed Web of Science ®Google Scholar
• Gilliet M, Kleinhans M, Lantelme E, et al. Intranodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen. Blood 2003; 102: 36–42
   PubMed Web of Science ®Google Scholar
• Avigan D, Vasir B, Gong J, et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 2004; 10: 4699–708
   PubMed Web of Science ®Google Scholar
• Bleyer WA. The impact of childhood cancer on the United States and the world. CA Cancer J Clin 1990; 40: 355–67
   PubMed Web of Science ®Google Scholar